JP2024545427A5 - - Google Patents
Info
- Publication number
- JP2024545427A5 JP2024545427A5 JP2024532762A JP2024532762A JP2024545427A5 JP 2024545427 A5 JP2024545427 A5 JP 2024545427A5 JP 2024532762 A JP2024532762 A JP 2024532762A JP 2024532762 A JP2024532762 A JP 2024532762A JP 2024545427 A5 JP2024545427 A5 JP 2024545427A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- combination according
- approximately
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306690 | 2021-12-02 | ||
| EP21306690.5 | 2021-12-02 | ||
| US202263383337P | 2022-11-11 | 2022-11-11 | |
| US63/383,337 | 2022-11-11 | ||
| PCT/EP2022/084105 WO2023099682A1 (en) | 2021-12-02 | 2022-12-01 | Ceacam5 adc–anti-pd1/pd-l1 combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545427A JP2024545427A (ja) | 2024-12-06 |
| JP2024545427A5 true JP2024545427A5 (https=) | 2025-12-08 |
Family
ID=84688547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532762A Pending JP2024545427A (ja) | 2021-12-02 | 2022-12-01 | Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組み合わせ療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250154250A1 (https=) |
| EP (1) | EP4440618A1 (https=) |
| JP (1) | JP2024545427A (https=) |
| KR (1) | KR20240112922A (https=) |
| AU (1) | AU2022402334A1 (https=) |
| CA (1) | CA3241254A1 (https=) |
| IL (1) | IL313223A (https=) |
| MX (1) | MX2024006765A (https=) |
| TW (1) | TW202340241A (https=) |
| WO (1) | WO2023099682A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| WO2020161214A1 (en) * | 2019-02-07 | 2020-08-13 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
| WO2025113646A1 (zh) * | 2023-11-30 | 2025-06-05 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| WO2025169012A1 (en) * | 2024-02-06 | 2025-08-14 | Sanofi | Methods of treating ceacam5-expressing cancers |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| WO2020161214A1 (en) | 2019-02-07 | 2020-08-13 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
| EP4138924A1 (en) * | 2020-04-24 | 2023-03-01 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri |
-
2022
- 2022-12-01 AU AU2022402334A patent/AU2022402334A1/en active Pending
- 2022-12-01 CA CA3241254A patent/CA3241254A1/en active Pending
- 2022-12-01 EP EP22830696.5A patent/EP4440618A1/en active Pending
- 2022-12-01 WO PCT/EP2022/084105 patent/WO2023099682A1/en not_active Ceased
- 2022-12-01 IL IL313223A patent/IL313223A/en unknown
- 2022-12-01 TW TW111146174A patent/TW202340241A/zh unknown
- 2022-12-01 US US18/715,558 patent/US20250154250A1/en active Pending
- 2022-12-01 MX MX2024006765A patent/MX2024006765A/es unknown
- 2022-12-01 KR KR1020247021673A patent/KR20240112922A/ko active Pending
- 2022-12-01 JP JP2024532762A patent/JP2024545427A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024545427A5 (https=) | ||
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2024545428A5 (https=) | ||
| JP6880006B2 (ja) | 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ | |
| Lutz | Targeting the folate receptor for the treatment of ovarian cancer | |
| JP2022523155A5 (https=) | ||
| Jiang et al. | HER2-targeted antibody drug conjugates for ovarian cancer therapy | |
| EP2833915A1 (en) | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies | |
| JP2022536854A5 (https=) | ||
| JP2024542095A5 (https=) | ||
| JP2023539589A5 (https=) | ||
| Salifu et al. | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer | |
| JP2025508380A5 (https=) | ||
| RU2024118187A (ru) | Комбинированная терапия, предусматривающая ceacam5-направленный adc с антителом к pd1/pd-l1 | |
| Colombo et al. | Antibody-drug conjugates in solid tumors | |
| RU2024118193A (ru) | Анализ на рэа отбора пациентов для противоопухолевой терапии | |
| WO2024193570A9 (en) | Combination of antibody-drug conjugate and cancer therapy, and use thereof | |
| EA050611B1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| HK40043732A (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| RU2024115286A (ru) | Противоопухолевые комбинации, содержащие конъюгаты антитела к ceacam5 и лекарственного средства и антитела к vegfr-2 | |
| RU2024117893A (ru) | Составы коронавирусной вакцины | |
| Zhou | Development and Evaluation of LSR-and CD276-Targeted Therapies for Triple-Negative Breast Cancer | |
| JP2024535034A5 (https=) | ||
| BR122024023393A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica |